Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

SCHLIEREN, Switzerland, LAUSANNE, Switzerland and SAN DIEGO, October 6 /PRNewswire/ --

Oncalis AG (Oncalis), a privately-owned Swiss biotechnology company, and ChemDiv Inc. (ChemDiv), a privately-owned, California-based discovery services company announced that they entered into an exclusive agreement for a license to Oncalis a family of PI3K inhibitors. ONC-201, the first development candidate from this family, is a potent and selective orally-bioavailable member of a new class of drugs targeting PI3-kinase. ONC-201 has demonstrated highly promising anti-cancer efficacy in pre-clinical cancer models.

SANTA CLARA, California, October 6 /PRNewswire/ --

SAN JOSE, California, October 6 /PRNewswire/ --

Atmel(R) Corporation (Nasdaq: ATML) has received a Readers Tech Choice award from eg3 for its embedded development kit for CryptoController(TM) (http://www.atmel.com/products/embedded/default.asp), Atmel's Trusted Platform Module (TPM) for non-PC, embedded applications. This kit also earned eg3's Editors Tech Choice Award. eg3.com is the leading non-biased news source for embedded systems, dsp, real-time/rtos, chip design, FPGA, and boards on the internet.

PARIS, October 6 /PRNewswire/ -- Alcan Global Pharmaceutical Packaging - a division of Alcan Packaging, a business unit of Rio Tinto Alcan - has acquired the Chakan flexible packaging plant from Associated Capsules Private Limited in India.

"The acquisition of this facility advances our leadership position in pharmaceutical flexibles through growth in emerging markets," said Ilene Gordon, president and chief executive officer, Alcan Packaging.

The Chakan operations both expand Alcan Packaging's geographic footprint and strengthen the organisation's strategic presence in the Indian pharmaceutical market, which is currently ranked 14th in the world in terms of scale and expected to triple over the next decade.

CALGARY, Canada, October 6 /PRNewswire/ --

- Hydresia(TM) G2 Approved by leading European Authority on Natural Organic Certification

TSX symbol: SBS

Botaneco Specialty Ingredients Inc. (Botaneco), a subsidiary of SemBioSys Genetics Inc. (SemBioSys), today announced that its second generation oleosome product, Hydresia(TM) G2, has been authorized by ECOCERT(R) as an approved raw material, complying with the standards for ecological and organic cosmetics. ECOCERT(R) is one of the largest organic control and certification organizations in the world and conducts inspections in over 80 countries. The company's primary focus is food and food products, cosmetics, detergents, perfumes, and textiles.

LONDON, October 6 /PRNewswire/ --

The organizers of Informex are delighted to announce their inaugural conference on Global Sourcing for the Pharmaceutical Industry, taking place November 10th-11th 2008 at the Princeton Marriott in New Jersey USA.

The conference is chaired by David Kinnear, President & CEO of the Global Sourcing Council, and boasts an unparalleled panel of key industry speakers including the likes of Johnson & Johnson, Bristol Myers Squibb, Genentech, Boehringer Ingelheim, and Roche Molecular Diagnostics.